The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How Microbes, Mycobacteria, and Metastases May Alter the Way We Look at Rheumatic Diseases

How Microbes, Mycobacteria, and Metastases May Alter the Way We Look at Rheumatic Diseases

October 1, 2012 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Dr. Helfgott, MD
Dr. Helfgott, MD

In his critically acclaimed book, Thinking, Fast and Slow, the Nobel laureate Daniel Kahneman lays out his theories about how we analyze and interpret data. Kahneman divides the thought process into two systems.1 System 1, or thinking fast, uses association and metaphor to generate a rapid analysis of the issue at hand. It functions quickly without deliberation, and does not require much oversight. Think autonomic nervous system. In contrast, System 2, responsible for thinking slowly, provides the more thoughtful, careful and reasoned analysis. It is probing and questions our assumptions about issues. System 2 represents the epitome of higher cortical brain function.

You Might Also Like
  • Practicing Mindfulness Can Help Alter Patients’ Experience with Chronic Rheumatic Diseases
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
Explore This Issue
October 2012
Also By This Author
  • Rheuminations: The Power of the Placebo

In one of Kahneman’s classic experiments assessing how one might enhance the activation of System 2, a group of Harvard undergraduate students were asked to solve a simple puzzle about the likely occupation of a hypothetical graduate student. They were provided with a set of variables including his possible fields of study and a personality sketch. “Half of the students were told to puff out their cheeks during the task, while the others were told to frown. It turns out that frowning generally increases the vigilance of System 2 and reduces both overconfidence and the reliance on intuition.” So, I am asking all readers to frown for the next several minutes as you read about some novel and interesting research findings. Intuitively, these studies may seem far afield from rheumatology. The first concerns the relationship between microbes and their hosts. The second describes the role for Bacille Calmette Guerin (BCG) as a vaccine that could attenuate type I diabetes. The third attempts to explain how an emotional stress such as depression can increase the risk of developing bone metastases in women with breast cancer. To paraphrase the late Steve Jobs, we need to be creative and “think different.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Gut of the Matter

This past summer, it would have been very difficult to avoid reading something about how microbial flora impacts our health. The human microbiome, a term coined by the late Joshua Lederberg, MD, consists of all microbes, their genomic material, and the sum total of their interactions within the host, namely each and every one of us. There are 10 times more microbial cells than human cells in the body. In total, the microbiome harbors 3,000 kinds of bacteria with 3 million distinct genes, compared with just 18,000 genes belonging to our own cells. In an excellent review of the topic, published in The Rheumatologist, Jose U. Scher, MD, clinical instructor of medicine, and Steven B. Abramson, MD, professor of medicine, both at the New York University School of Medicine, describe how the gut microbiota should be viewed as an extension of the self.2 As the authors stress, its rich milieu contains far more genetic and antigenic material than the host. They lay out in elegant detail how the microbiome may drive the pathogenesis of rheumatic diseases such as rheumatoid arthritis (RA) and the spondylarthropathies.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis, Rheuminations, SLE (Lupus), Spondyloarthritis Tagged With: Cancer, gut microbiome, Helfgott, Lupus, microbe, Microbiome, patient care, vaccineIssue: October 2012

You Might Also Like:
  • Practicing Mindfulness Can Help Alter Patients’ Experience with Chronic Rheumatic Diseases
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • 2015 ACR/ARHP Annual Meeting: Skin Issues in Rheumatic Diseases Present Challenges

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.